Alzheimer's drug demand lags as estrogen patches face supply shortages

Summary

Recently approved medications for Alzheimer's disease, specifically Leqembi and Kisunla, are not reaching as many patients as federal officials originally expected. Medicare adoption for these treatments is significantly lower than initial projections. This sluggish demand stems from several practical and medical hurdles that make the drugs challenging to use.

The slow rollout is tied to the strict requirements for administering these therapies. Patients must receive the medication through an intravenous drip and undergo frequent medical imaging. On top of these logistical hurdles, the drugs are only suitable for a limited group of eligible patients. Finally, the medications carry the risk of severe side effects, including brain bleeding, which can make both doctors and patients cautious.

In a separate medical trend, estrogen patches are becoming increasingly difficult to find. Hormone replacement therapy has seen a massive boom in popularity since the Food and Drug Administration removed a severe safety alert, known as a black box warning, from the treatments late last year. While the American Society of Health-System Pharmacists reports that 14 different brands or dosages of estrogen patches are currently in short supply, it is worth noting that the FDA has not yet officially added them to its own drug shortage list.

Why it matters.

The surprisingly low adoption of new Alzheimer's treatments highlights a major gap between scientific milestones and everyday clinical practice. Even when highly anticipated drugs reach the market, their real-world impact is heavily restricted if they are difficult to administer, require extensive monitoring, or pose severe health risks. For the healthcare system, this translates to far lower Medicare spending than projected, but for patients, it underscores the ongoing need for safer and more accessible memory care treatments.

Meanwhile, the rising demand for hormone replacement therapy reveals how quickly patient behavior shifts when regulatory warnings change. The sudden shortage of estrogen patches leaves many patients scrambling for relief. The discrepancy between pharmacy reports of 14 missing patch dosages and the official FDA list points to potential delays in how drug shortages are officially tracked, which can slow down the institutional responses needed to help patients get their daily medications.

From the source

The story in numbers.

Brands or dosages of estrogen patches on ASHP shortage list: 14
Years for which Medicare removed significant spending forecasts for new Alzheimer's drugs: 2026 and 2027

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

Follow your curiosity.

Alzheimer's drug demand lags as estrogen patches face supply shortages

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

A $122M boost for a fast, inside-the-body approach to cell therapy

Supreme Court Protects Access to Common Abortion Pill

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

A $122M boost for a fast, inside-the-body approach to cell therapy

Supreme Court Protects Access to Common Abortion Pill

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

A little science goes a long way.